Medindia

X

Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2011 Results

Friday, May 6, 2011 General News J E 4
Advertisement

WALTHAM, Mass., May 5, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, May 12, 2011 at 4:30 p.m. ET to discuss the Company's first quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.'s Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand.  The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information please visit www.ilgenetics.com.

Contact:Eliot M. Lurier, CFOInterleukin Genetics, Inc.781-398-0700 X-1204elurier@ilgenetics.com

SOURCE Interleukin Genetics, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Anadys Pharmaceuticals Reports First Quarter 2011 ...
S
CareFusion Reports Third Quarter Rise in Revenue, ...